Literature DB >> 7466320

Platelet function in preleukaemia.

R Lintula, V Rasi, E Ikkala, G H Borgström, P Vuopio.   

Abstract

Platelet function was studied in 17 patients with preleukaemia and the results were compared with those of 28 patients with other chronic myeloproliferative disorders. The test pattern included bleeding time (Ivy), platelet retention (Hellem II), PF-3 activity and availability after exposure to ADP and kaolin, and ADP-, epinephrine-, collagen- and ristocetin-induced aggregations. Platelet function was frequently impaired in patients with preleukemia. The defects were similar to those found in other myeloproliferative disorders. The most consistent finding was defective aggregation. Patients with thrombocytosis and/or with increased amounts of megakaryocytes in the bone marrow had fewer defects in platelet function. Retention defect was more common in patients with hypolobulated megakaryocytes, especially in those having a specific marker, the 5q- chromosome, in their bone marrow cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7466320     DOI: 10.1111/j.1600-0609.1981.tb01626.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  5 in total

Review 1.  The myelodysplastic syndromes.

Authors:  D M Layton; G J Mufti
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-25

2.  Impaired T-cell and NK-cell function in patients with preleukemia.

Authors:  F Porzsolt; H Heimpel
Journal:  Blut       Date:  1982-10

3.  Platelet dysfunction as the presenting feature of atypical myelodysplastic syndrome with monosomy 7, normal blood counts and no bleeding tendency.

Authors:  D Marisavljević; P Antunović; P Miljić; M Pantić
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 4.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

Review 5.  Human preleukaemia: do we have a model?

Authors:  A Jacobs
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.